The PET radiopharmaceutical [18F]Fluromisonidazole ([18F]FMISO) is presently the agent of choice for the clinical imaging of tumor hypoxia. Considering the logistic advantages of 99mTc and wider availability of SPECT machines, a 99mTc-radiopharmaceutical for this purpose constitutes an attractive choice. In the work presented here, a misonidazole analogue was radiolabeled with 99mTc(CO)3 core and the complex was evaluated in Swiss mice bearing fibrosarcoma tumor. The results obtained are compared with the biodistribution of [18F]FMISO carried out in the same tumor-bearing animal model. Misonidazole-99mTc(CO)3 complex showed significant uptake and retention in tumor. Notably, the rate of clearance of misonidazole complex from the tumor was slower than that of [18F]FMISO. The maximum tumor/muscle ratio obtained with misonidazole-99mTc(CO)3 complex was significantly higher than that of [18F]FMISO. The study constitutes a positive step toward the development of a 99mTc-analogue of [18F]FMISO.
MeesG, DierckxR, VangestelC, et al.Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging, 2009; 36:1674.
3.
HöckelM, SchlengerK, AralB, et al.Association between tumor hypoxia and malignant progression. Cancer Res, 1996; 56:4509.
4.
FylesAW, MilosevicM, WongR, et al.Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol, 1998; 48:149.
5.
NordsmarkM, OvergaardM, OvergaardJ. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol, 1996; 41:31.
6.
BrizelDM, SibleyGS, ProsnitzLR, et al.Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys, 1997; 38:285.
7.
NordsmarkM, BentzenSM, RudatV, et al.Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol, 2005; 77:18.
8.
DuffyJP, EiblG, ReberHA, et al.Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer, 2003; 2:12.
9.
BrizelDM, ScullySP, HarrelsonJM, et al.Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res, 1996; 56:941.
RaseyJS, HofstrandPD, ChinLK, et al.Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. Nucl Med, 1999; 40:1072.
12.
KachurAV, DolbierWRJr., EvansSM, et al.Synthesis of new hypoxia markers EF1 and [18F]-EF1. Appl Radiat Isot, 1999; 51:643.
13.
KomarG, SeppänenM, EskolaO, et al.18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med, 2008; 49:1944.
14.
CouturierO, LuxenA, ChatalJC, et al.Eur. Fluorinated tracers for imaging cancer with positron emission tomography. J Nucl Med Mol Imaging, 2004; 31:1182.
15.
DolbierWRJr., LiAR, KochCJ, et al.[18F]EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot, 2001; 54:73.
16.
MahyP, De BastM, GillartJ, et al.Detection of tumour hypoxia: Comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging, 2006; 33:553.
17.
PiertM, MachullaHJ, PicchioM, et al.Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med, 2005; 46:106.
18.
ReischlG, DorowDS, CullinaneC, et al.Imaging of hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA-first small animal PET results. J Pharm Pharm Sci, 2007; 10:203.
19.
Talbotet al.PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: Preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging, 2006; 33:1285.
20.
RahmimAet al.PET versus SPECT: Strengths, limitations and challenges. Nucl Med Commun, 2008; 29:193.
21.
LinderKEet al.Synthesis, characterization, and in vitro evaluation of nitroimidazole-BATO complexes: New technetium compounds designed for imaging hypoxic tissue. Bioconjug Chem, 1993; 4:326.
22.
LinderKEet al.TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem, 1994; 37:9.
23.
Ballingeret al.In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med, 1996; 37:1023.
24.
MeloTet al.BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. Biochem Pharmacol, 1997; 54:685.
25.
YangDJet al.Noninvasive assessment of tumor hypoxia with 99mTc labeled metronidazole. Pharm Res, 1999; 16:743.
26.
SuZFet al.Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia. Bioconjug Chem, 1999; 10:897.
27.
ZhangX, SuZF, BallingerJR, et al.Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for Technetium-99m: Effect of lipophilicity. Bioconjug Chem, 2000; 11:401.
28.
SuZFet al.A novel amine-dioxime chelator for technetium-99m: Synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells. Bioconjug Chem, 2000; 11:652.
29.
RichéF, d'HardemareAD, SèpeS, et al.Nitroimidazoles and hypoxia imaging: Synthesis of three technetium-99m complexes bearing a nitroimidazole group: Biological results. Bioorg Med Chem Lett, 2001; 11:71.
30.
ChuT, HuS, WeiB, et al.Synthesis and biological results of the technetium-99m-labeled 4-nitroimidazole for imaging tumor hypoxia. Bioorg Med Chem Lett, 2004; 14:747.
31.
ChuT, LiR, HuS, et al.Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker. Nucl Med Biol, 2004; 31:199.
32.
HuangH, ZhouH, LiZ, et al.Effect of a second nitroimidazole redox centre on the accumulation of a hypoxia marker: Synthesis and in vitro evaluation of 99mTc-labeled bisnitroimidazole propylene amine oxime complexes. Bioorg Med Chem Lett, 2012; 22:172.
33.
GiglioJ, FernándezS, PietzschHJ, et al.Synthesis, in vitro and in vivo characterization of novel 99mTc-‘4+1’-labeled 5-nitroimidazole derivatives as potential agents for imaging hypoxia. Nucl Med Biol, 2012; 39:679.
34.
FernándezS, GiglioJ, ReyAM, et al.Influence of ligand denticity on the properties of novel 99mTc(I)–carbonyl complexes. Application to the development of radiopharmaceuticals for imaging hypoxic tissue. Bioorg Med Chem, 2012; 20:4040.
35.
MeiL, WangY, ChuT. 99mTc/Re complexes bearing bisnitroimidazole or mononitroimidazole as potential bioreductive markers for tumor: Synthesis, physicochemical characterization and biological evaluation. Eur J Med Chem, 2012; 58:50.
36.
LiN, ZhuH, ChuTW, et al.Preparation and biological evaluation of 99mTc-N4IPA for single photon emission computerized tomography imaging of hypoxia in mouse tumor. Eur J Med Chem, 2013; 69:223.
37.
MalliaMB, SubramanianS, MathurA, et al.A study on nitroimidazole-99mTc(CO)3 complexes as hypoxia marker: Some observations towards possible improvement in in vivo efficacy. Nucl Med Biol, 2014; 41:600.
38.
HoebersFJ, JanssenHL, OlmosAV, et al.Phase 1 study to identify tumour hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21. Eur J Nucl Med Mol Imaging, 2002; 29:1206.
39.
MathurA, MalliaMB, BanerjeeS, et al.Preparation and evaluation of a 99mTcN-PNP complex of sanazole analogue for detecting tumor hypoxia. Bioorg Med Chem Lett, 2013; 23:1394.
40.
MalliaMB, KumarC, MathurA, et al.On the structural modification of 2-nitroimidazole-(99m)Tc(CO)(3) complex, a hypoxia marker, for improving in vivo pharmacokinetics. Nucl Med Biol, 2012; 39:1236.
41.
MalliaMB, SubramanianS, MathurA, et al.Synthesis and evaluation of 2-, 4-, 5-substituted nitroimidazole-iminodiacetic acid-99mTc(CO)3 complexes to target hypoxic tumors. J Label Compd Radiopharm, 2010; 53:535.
42.
Malliaet al.On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. Bioorg Med Chem Lett, 2008; 18:5233.
43.
Malliaet al.Comparing hypoxia-targeting potential of 99mTc(CO)3-labeled 2-nitro and 4-nitroimidazole. J Label Compd Radiopharm, 2008; 51:308.
44.
Malliaet al.Evaluation of 99mTc(CO)3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumour hypoxia. Bioorg Med Chem, 2006; 14:7666.
45.
Malliaet al.A novel [99mTcN]+2 complex of metronidazole xanthate for possible use in imaging hypoxia. Bioorg Med Chem Lett, 2005; 15:3398.
46.
WardmanP. Reduction potentials of one-electron couples involving free radicals in aqueous solution. J Phys Chem Ref Data, 1989; 18:1637.
47.
AbramU, AlbertoR. Technetium and rhenium—coordination chemistry and nuclear medical applications. J Braz Chem Soc, 2006; 17:1486.
48.
AlbertoR, SchibliR, EgliA, et al.Novel organometallic aqua complex of technetium for the labeling of biomolecules: synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]− in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc, 1998; 120:7987.
49.
SchibliR, La BellaR, AlbertoR, et al.Influence of the denticity of ligand systems on the in vitro and invivo behavior of (99m)Tc(I)-tricarbonyl complexes: A hint for the future functionalization of biomolecules. Bioconjug Chem, 2000; 11:345.
50.
TroutnerDE, VolkertWA, HoffmanTJ, et al.A neutral lipophilic complex of 99mTc with a multidentate amine oxime. Int J Appl Radiat Isot, 1984; 35:467.
